Literature DB >> 28464701

Preliminary Evidence on Cannabis Effectiveness and Tolerability for Adults With Tourette Syndrome.

Elia Abi-Jaoude1, Lei Chen1, Patrina Cheung1, Tracy Bhikram1, Paul Sandor1.   

Abstract

The authors retrospectively evaluated effectiveness and tolerability of cannabis in 19 adults with Tourette syndrome. Tics scores decreased by 60%, and 18 of the 19 participants were at least "much improved." Cannabis was generally well tolerated, although most participants reported side effects.

Entities:  

Keywords:  Basal Ganglia Disorders; Drug/Psychotherapy Treatment of Neuropsychiatric Disorders; Neuropharmacology; Outcome Studies Biological/Pharmacological

Mesh：

Substances：

Year:  2017        PMID： 28464701     DOI： 10.1176/appi.neuropsych.16110310

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN： 0895-0172            Impact factor:   2.198


  10 in total

1.  Treatment of Gilles de la Tourette Syndrome with Cannabis-Based Medicine: Results from a Retrospective Analysis and Online Survey.

Authors:  Leonie M Milosev; Nikolas Psathakis; Natalia Szejko; Ewgeni Jakubovski; Kirsten R Müller-Vahl
Journal:  Cannabis Cannabinoid Res       Date:  2019-12-09

2.  The Potential of Cannabinoid-Based Treatments in Tourette Syndrome.

Authors:  Bekir B Artukoglu; Michael H Bloch
Journal:  CNS Drugs       Date:  2019-05       Impact factor: 5.749

Review 3.  Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders.

Authors:  Tamara Pringsheim; Michael S Okun; Kirsten Müller-Vahl; Davide Martino; Joseph Jankovic; Andrea E Cavanna; Douglas W Woods; Michael Robinson; Elizabeth Jarvie; Veit Roessner; Maryam Oskoui; Yolanda Holler-Managan; John Piacentini
Journal:  Neurology       Date:  2019-05-07       Impact factor: 11.800

4.  Cerebrospinal fluid endocannabinoid levels in Gilles de la Tourette syndrome.

Authors:  Kirsten R Müller-Vahl; Laura Bindila; Beat Lutz; Frank Musshoff; Thomas Skripuletz; Charlotte Baumgaertel; Kurt-Wolfram Sühs
Journal:  Neuropsychopharmacology       Date:  2020-04-09       Impact factor: 7.853

Review 5.  Cannabis and Its Secondary Metabolites: Their Use as Therapeutic Drugs, Toxicological Aspects, and Analytical Determination.

Authors:  Joana Gonçalves; Tiago Rosado; Sofia Soares; Ana Y Simão; Débora Caramelo; Ângelo Luís; Nicolás Fernández; Mário Barroso; Eugenia Gallardo; Ana Paula Duarte
Journal:  Medicines (Basel)       Date:  2019-02-23

6.  Medical Cannabis for Gilles de la Tourette Syndrome: An Open-Label Prospective Study.

Authors:  Saar Anis; Corinne Zalomek; Amos D Korczyn; Alina Rosenberg; Nir Giladi; Tanya Gurevich
Journal:  Behav Neurol       Date:  2022-03-09       Impact factor: 3.342

7.  Endocannabinoid Modulation Using Monoacylglycerol Lipase Inhibition in Tourette Syndrome: A Phase 1 Randomized, Placebo-Controlled Study.

Authors:  Kirsten R Müller-Vahl; Carolin Fremer; Chan Beals; Jelena Ivkovic; Henrik Loft; Christoph Schindler
Journal:  Pharmacopsychiatry       Date:  2021-11-30       Impact factor: 2.544

Review 8.  Cannabinoids and the expanded endocannabinoid system in neurological disorders.

Authors:  Luigia Cristino; Tiziana Bisogno; Vincenzo Di Marzo
Journal:  Nat Rev Neurol       Date:  2019-12-12       Impact factor: 42.937

Review 9.  A Comprehensive Review of Tourette Syndrome and Complementary Alternative Medicine.

Authors:  Ashutosh Kumar; L Duda; G Mainali; S Asghar; D Byler
Journal:  Curr Dev Disord Rep       Date:  2018-03-27

10.  Association of a Variant of CNR1 Gene Encoding Cannabinoid Receptor 1 With Gilles de la Tourette Syndrome.

Authors:  Natalia Szejko; Jakub Piotr Fichna; Krzysztof Safranow; Tomasz Dziuba; Cezary Żekanowski; Piotr Janik
Journal:  Front Genet       Date:  2020-03-04       Impact factor: 4.599
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.